stock poised for growth as pipeline advances By Investing.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:), a biopharmaceutical company focused on developing treatments for rare endocrine diseases and endocrine-related tumors, is on the cusp of a significant transformation. As the company prepares to transition from a clinical-stage to a commercial-stage entity, investors and analysts are closely watching its progress in advancing its pipeline and navigating regulatory hurdles.
Pipeline Overview
CRNX’s pipeline is anchored by two key candidates: paltusotine and atumelnant. Paltusotine, an oral somatostatin receptor agonist, is being developed for the treatment of acromegaly and carcinoid syndrome. The company has submitted a New Drug Application (NDA) for paltusotine in acromegaly, with expectations…
